While somatic mutations of PARK2 that decrease PARK2’s E3 ligase activity, compromising its ability to ubiquitinate cyclin E, are associated with cancer [121, 122], germline mutations of PARK2 were identified in patients with autosomal recessive juvenile Parkinsonism (ARJP) [123]. The gene discussed is PRKN; the disease is cancer.